Acorda to Host Conference Call to Discuss Second Quarter 2016 on July 28, 2016
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2016 financial
results and pipeline updates on Thursday, July 28 at 8:30 a.m. ET.
To participate in the conference call, please dial (855) 542-4209 (domestic) or (412) 455-6054 (international) and reference the
access code 40809722. The presentation will be available on the Investors section of www.acorda.com. Please log in approximately 5 minutes before the scheduled time of the presentation to ensure a
timely connection.
A replay of the call will be available from 11:30 a.m. ET on July 28, 2016 until 11:59 p.m. ET on August 4, 2016. To access the
replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference the access code 40809722. The
archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and
improve the lives of people with neurological disorders.
Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s
disease, post-stroke walking difficulties, migraine, and multiple sclerosis. Acorda markets three FDA-approved therapies,
including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
For more information, please visit the Company’s website at: www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to
risks and uncertainties that could cause actual results to differ materially, including: the ability to complete the Biotie
transaction on a timely basis; the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among
other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process
and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the ability to successfully
integrate Biotie’s operations and Civitas’ operations, respectively, into our operations; we may need to raise additional funds to
finance our expanded operations and may not be able to do so on acceptable terms; our ability to successfully market and sell
Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the U.S.; third party payers (including governmental agencies) may
not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior
authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from
our other research and development programs, including CVT-301 or any other acquired or in-licensed programs; we may not be able to
complete development of, obtain regulatory approval for, or successfully market CVT-301, any other products under development, or
the products that we will acquire when we complete the Biotie transaction; the occurrence of adverse safety events with our
products; delays in obtaining or failure to obtain and maintain regulatory approval of or to successfully market Fampyra outside of
the U.S. and our dependence on our collaborator Biogen in connection therewith; competition; failure to protect our intellectual
property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses
needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action
by regulatory agencies.
These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on
these statements. Forward-looking statements made in this presentation are made only as of the date hereof, and we disclaim any
intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this
presentation.
Acorda Therapeutics
Felicia Vonella, 914-326-5146
fvonella@acorda.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160707005004/en/